Short answer
VIEMED HEALTHCARE, INC. (VMD) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 and nine-month fiscal 2026 results announced for periods ended September 30, 2026.
VIEMED HEALTHCARE, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month fiscal 2026 results announced for periods ended September 30, 2026
- Financial Supplement provides additional operating and financial detail for investor analysis
- Results and supplement attached as Exhibits 99.1 and 99.2
Item 7.01 · Regulation FD Disclosure
- Investor deck published as Exhibit 99.3 and available on Viemed’s investor website
- Presentation intended for investor and analyst meetings, signaling updated corporate messaging
- Deck should be reviewed for management’s strategic priorities, operating metrics and financial outlook
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue reached a record $80.7M, up 12.2% year over year and 3.3% sequentially, confirming diversified growth momentum
- Net income attributable to Viemed rose 32.0% year over year to $4.6M, while diluted EPS increased to $0.11
- Adjusted EBITDA grew 24.4% sequentially to $17.1M, with margin expanding to 21.1% from 17.6%
- PAP therapy patients rose 37.5% year over year to 43,861, supporting less capital-intensive growth beyond ventilator rentals
- 2026 guidance improved: revenue floor raised to $316M, Adjusted EBITDA narrowed to $64M-$66M, and net CAPEX reduced to 8.0%-9.0% of revenue
Item EX-99.2 · Exhibit EX-99.2
- Record Q3 revenue $80.7M, up 12.2% YoY and 3.3% sequentially, confirming continued platform expansion
- Net income $4.6M, up 32.0% YoY, with diluted EPS $0.11 and margin improving to 5.7%
- Adjusted EBITDA $17.1M, up 24.4% sequentially, lifting margin to 21.1% from 17.6%
- PAP patients reached 43,861, up 37.5% YoY, while sleep resupply patients reached 40,918, up 22.1%
- Full-year guidance narrowed to revenue $316M-$320M and Adjusted EBITDA $64M-$66M, with net CAPEX reduced to 8.0%-9.0% of revenue
Item EX-99.3 · Exhibit EX-99.3
- 2026 guidance: net revenue $316M-$320M and Adjusted EBITDA $64M-$66M, signaling continued double-digit growth
- Q3 2026 revenue $80.7M, up 12% YoY, with ventilator rental revenue up 7.4% to $37.5M
- Sleep remains the key growth engine: PAP patients up 38% and resupply patients up 22% YoY
- New repurchase authorization up to 5% of shares outstanding, with 795,802 shares already repurchased at $9.47 average
- Financial flexibility supports acquisitions and buybacks: $0M net debt and $46M available credit as of September 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other VIEMED HEALTHCARE, INC. 8-K filings
Get the next VMD 8-K as it lands
Follow VMD for push alerts, or ask the research agent what this filing means.